Cargando…
Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese patients with metastatic colorectal cancer (mCRC). Clinical data were collected from a single-center registry study wh...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181797/ https://www.ncbi.nlm.nih.gov/pubmed/28002313 http://dx.doi.org/10.1097/MD.0000000000004531 |
_version_ | 1782485769120645120 |
---|---|
author | Bai, Long Wang, Feng Li, Zhe-zhen Ren, Chao Zhang, Dong-sheng Zhao, Qi Lu, Yun-xin Wang, De-shen Ju, Huai-qiang Qiu, Miao-zhen Wang, Zhi-qiang Wang, Feng-hua Xu, Rui-hua |
author_facet | Bai, Long Wang, Feng Li, Zhe-zhen Ren, Chao Zhang, Dong-sheng Zhao, Qi Lu, Yun-xin Wang, De-shen Ju, Huai-qiang Qiu, Miao-zhen Wang, Zhi-qiang Wang, Feng-hua Xu, Rui-hua |
author_sort | Bai, Long |
collection | PubMed |
description | The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese patients with metastatic colorectal cancer (mCRC). Clinical data were collected from a single-center registry study where mCRC patients received first-line fluoropyrimidine-based chemotherapy combined with either bevacizumab (188 patients with KRAS wild-type or mutated tumors) or cetuximab (101 patients with KRAS wild-type tumors) between January 2009 and December 2013. The Kaplan–Meier method was used for survival analysis. Cox proportional hazards model was used for estimating the prognostic and predictive values of clinicopathological characteristics. No statistically significant difference was observed between the bevacizumab and cetuximab groups in terms of median progression-free survival (PFS) (10.6 vs 8.7 months, P = 0.317), median overall survival (OS) (27.7 vs 28.3 months, P = 0.525), or overall response rate (43.1% vs 53.5%, P = 0.108). For the subset of patients with peritoneal dissemination, bevacizumab-based triplet appears to be superior to cetuximab-based triplet as measured by PFS (9.6 vs 6.1 months) and OS (26.3 vs 12.7 months), but not for patients without peritoneal dissemination (PFS, 10.6 vs 9.1 months; OS, 27.9 vs 30.7 months) (all unadjusted and adjusted interaction P < 0.05). Our study suggests that bevacizumab- or cetuximab-based regimens have similar effectiveness as first-line treatment of mCRC in Chinese population. Patients with peritoneal dissemination were likely to gain more benefit from bevacizumab than cetuximab treatment. Future prospective studies are required to further confirm these results. |
format | Online Article Text |
id | pubmed-5181797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-51817972016-12-28 Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis Bai, Long Wang, Feng Li, Zhe-zhen Ren, Chao Zhang, Dong-sheng Zhao, Qi Lu, Yun-xin Wang, De-shen Ju, Huai-qiang Qiu, Miao-zhen Wang, Zhi-qiang Wang, Feng-hua Xu, Rui-hua Medicine (Baltimore) 5700 The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese patients with metastatic colorectal cancer (mCRC). Clinical data were collected from a single-center registry study where mCRC patients received first-line fluoropyrimidine-based chemotherapy combined with either bevacizumab (188 patients with KRAS wild-type or mutated tumors) or cetuximab (101 patients with KRAS wild-type tumors) between January 2009 and December 2013. The Kaplan–Meier method was used for survival analysis. Cox proportional hazards model was used for estimating the prognostic and predictive values of clinicopathological characteristics. No statistically significant difference was observed between the bevacizumab and cetuximab groups in terms of median progression-free survival (PFS) (10.6 vs 8.7 months, P = 0.317), median overall survival (OS) (27.7 vs 28.3 months, P = 0.525), or overall response rate (43.1% vs 53.5%, P = 0.108). For the subset of patients with peritoneal dissemination, bevacizumab-based triplet appears to be superior to cetuximab-based triplet as measured by PFS (9.6 vs 6.1 months) and OS (26.3 vs 12.7 months), but not for patients without peritoneal dissemination (PFS, 10.6 vs 9.1 months; OS, 27.9 vs 30.7 months) (all unadjusted and adjusted interaction P < 0.05). Our study suggests that bevacizumab- or cetuximab-based regimens have similar effectiveness as first-line treatment of mCRC in Chinese population. Patients with peritoneal dissemination were likely to gain more benefit from bevacizumab than cetuximab treatment. Future prospective studies are required to further confirm these results. Wolters Kluwer Health 2016-12-23 /pmc/articles/PMC5181797/ /pubmed/28002313 http://dx.doi.org/10.1097/MD.0000000000004531 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Bai, Long Wang, Feng Li, Zhe-zhen Ren, Chao Zhang, Dong-sheng Zhao, Qi Lu, Yun-xin Wang, De-shen Ju, Huai-qiang Qiu, Miao-zhen Wang, Zhi-qiang Wang, Feng-hua Xu, Rui-hua Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis |
title | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis |
title_full | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis |
title_fullStr | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis |
title_full_unstemmed | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis |
title_short | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis |
title_sort | chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: results of a registry-based cohort analysis |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181797/ https://www.ncbi.nlm.nih.gov/pubmed/28002313 http://dx.doi.org/10.1097/MD.0000000000004531 |
work_keys_str_mv | AT bailong chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT wangfeng chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT lizhezhen chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT renchao chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT zhangdongsheng chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT zhaoqi chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT luyunxin chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT wangdeshen chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT juhuaiqiang chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT qiumiaozhen chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT wangzhiqiang chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT wangfenghua chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis AT xuruihua chemotherapyplusbevacizumabversuschemotherapypluscetuximabasfirstlinetreatmentforpatientswithmetastaticcolorectalcancerresultsofaregistrybasedcohortanalysis |